Breaking News

Tuesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Lumos Pharma to host conference call » 13:45
12/06/22
12/06
13:45
12/06/22
13:45
LUMO

Lumos Pharma

$5.12 /

+ (+0.00%)

Management holds a KOL…

Management holds a KOL conference call to discuss interim data from the Phase 2 OraGrowtH210 and PK/PD OraGrowtH212 Trials evaluating oral LUM-201 in Pediatric Growth Hormone Deficiency (PGHD) on December 6 at 2 pm. Webcast Link

ShowHide Related Items >><<
LUMO Lumos Pharma
$5.12 /

+ (+0.00%)

LUMO Lumos Pharma
$5.12 /

+ (+0.00%)

11/15/22 Jefferies
Lumos Pharma downgraded to Hold from Buy at Jefferies (yesterday)
11/14/22 Piper Sandler
Piper 'not concerned' about two outliers in Lumos' OraGrowtH210 rhGH cohort
11/14/22 Jefferies
Lumos Pharma downgraded to Hold from Buy at Jefferies
07/19/22 Oppenheimer
Lumos Pharma initiated with an Outperform at Oppenheimer
Conference/Events
Lumos Pharma to host conference call » 04:55
12/06/22
12/06
04:55
12/06/22
04:55
LUMO

Lumos Pharma

$5.12 /

-0.03 (-0.58%)

Management holds a KOL…

Management holds a KOL conference call to discuss interim data from the Phase 2 OraGrowtH210 and PK/PD OraGrowtH212 Trials evaluating oral LUM-201 in Pediatric Growth Hormone Deficiency (PGHD) on December 6 at 2 pm. Webcast Link

ShowHide Related Items >><<
LUMO Lumos Pharma
$5.12 /

-0.03 (-0.58%)

LUMO Lumos Pharma
$5.12 /

-0.03 (-0.58%)

11/15/22 Jefferies
Lumos Pharma downgraded to Hold from Buy at Jefferies (yesterday)
11/14/22 Piper Sandler
Piper 'not concerned' about two outliers in Lumos' OraGrowtH210 rhGH cohort
11/14/22 Jefferies
Lumos Pharma downgraded to Hold from Buy at Jefferies
07/19/22 Oppenheimer
Lumos Pharma initiated with an Outperform at Oppenheimer
Monday
Conference/Events
Lumos Pharma to host conference call » 17:35
12/05/22
12/05
17:35
12/05/22
17:35
LUMO

Lumos Pharma

$5.12 /

-0.03 (-0.58%)

Management holds a KOL…

Management holds a KOL conference call to discuss interim data from the Phase 2 OraGrowtH210 and PK/PD OraGrowtH212 Trials evaluating oral LUM-201 in Pediatric Growth Hormone Deficiency (PGHD) on December 6 at 2 pm. Webcast Link

ShowHide Related Items >><<
LUMO Lumos Pharma
$5.12 /

-0.03 (-0.58%)

LUMO Lumos Pharma
$5.12 /

-0.03 (-0.58%)

11/15/22 Jefferies
Lumos Pharma downgraded to Hold from Buy at Jefferies (yesterday)
11/14/22 Piper Sandler
Piper 'not concerned' about two outliers in Lumos' OraGrowtH210 rhGH cohort
11/14/22 Jefferies
Lumos Pharma downgraded to Hold from Buy at Jefferies
07/19/22 Oppenheimer
Lumos Pharma initiated with an Outperform at Oppenheimer
Over a week ago
Downgrade
Lumos Pharma downgraded to Hold from Buy at Jefferies (yesterday) » 08:04
11/15/22
11/15
08:04
11/15/22
08:04
LUMO

Lumos Pharma

$5.92 /

-3.03 (-33.85%)

Jefferies analyst Eun…

Jefferies analyst Eun Yang yesterday afternoon downgraded Lumos Pharma to Hold from Buy with a price target of $7, down from $17. The interim Phase 2b LUM-201 data shows annual growth rates in line with the company's expectation, but numerically lower versus current therapy in moderate pediatric growth hormone deficiency, Yang tells investors in a research note. The analyst downgraded Lumos on "yet-to-be seen numerically comparable efficacy" verses current therapy, potential financing risk at the low share price and Lumos' "limited" intellectual property protection.

ShowHide Related Items >><<
LUMO Lumos Pharma
$5.92 /

-3.03 (-33.85%)

LUMO Lumos Pharma
$5.92 /

-3.03 (-33.85%)

11/14/22 Piper Sandler
Piper 'not concerned' about two outliers in Lumos' OraGrowtH210 rhGH cohort
11/14/22 Jefferies
Lumos Pharma downgraded to Hold from Buy at Jefferies
07/19/22 Oppenheimer
Lumos Pharma initiated with an Outperform at Oppenheimer
05/10/22 Piper Sandler
Upcoming topline data could drive Lumos Pharma share gains, says Piper Sandler
Recommendations
Piper 'not concerned' about two outliers in Lumos' OraGrowtH210 rhGH cohort » 16:35
11/14/22
11/14
16:35
11/14/22
16:35
LUMO

Lumos Pharma

$5.92 /

-3.03 (-33.85%)

After Lumos Pharma…

After Lumos Pharma reported interim results from OraGrowtH210 and 212, Piper Sandler analyst Yasmeen Rahimi said AHV came in as expected, but it was lower than the rhGH arm. While two outliers in the OraGrowtH210 rhGH cohort impacted the stock, Rahimi is "not concerned about this for the full population" and believes this readout de-risks LUM-201 heading into full results in the second half of 2023. Rahimi, who argues that the interim results "validate LUM-201 as an oral therapy for PGHD," keeps an Overweight rating and $26 price target on Lumos shares, which closed $3.09, or 35%, lower on Monday at $5.82.

ShowHide Related Items >><<
LUMO Lumos Pharma
$5.92 /

-3.03 (-33.85%)

LUMO Lumos Pharma
$5.92 /

-3.03 (-33.85%)

11/14/22 Jefferies
Lumos Pharma downgraded to Hold from Buy at Jefferies
07/19/22 Oppenheimer
Lumos Pharma initiated with an Outperform at Oppenheimer
05/10/22 Piper Sandler
Upcoming topline data could drive Lumos Pharma share gains, says Piper Sandler
Downgrade
Lumos Pharma downgraded to Hold from Buy at Jefferies » 15:42
11/14/22
11/14
15:42
11/14/22
15:42
LUMO

Lumos Pharma

$6.53 /

-2.42 (-27.04%)

Jefferies analyst Eun…

Jefferies analyst Eun Yang downgraded Lumos Pharma to Hold from Buy.

ShowHide Related Items >><<
LUMO Lumos Pharma
$6.53 /

-2.42 (-27.04%)

LUMO Lumos Pharma
$6.53 /

-2.42 (-27.04%)

07/19/22 Oppenheimer
Lumos Pharma initiated with an Outperform at Oppenheimer
05/10/22 Piper Sandler
Upcoming topline data could drive Lumos Pharma share gains, says Piper Sandler
Over a month ago
Conference/Events
Lumos Pharma management to meet virtually with Oppenheimer » 04:55
09/26/22
09/26
04:55
09/26/22
04:55
LUMO

Lumos Pharma

$9.00 /

-0.255 (-2.76%)

Virtual Meeting to be…

Virtual Meeting to be held on September 26 hosted by Oppenheimer.

ShowHide Related Items >><<
LUMO Lumos Pharma
$9.00 /

-0.255 (-2.76%)

LUMO Lumos Pharma
$9.00 /

-0.255 (-2.76%)

07/19/22 Oppenheimer
Lumos Pharma initiated with an Outperform at Oppenheimer
05/10/22 Piper Sandler
Upcoming topline data could drive Lumos Pharma share gains, says Piper Sandler
LUMO Lumos Pharma
$9.00 /

-0.255 (-2.76%)

Conference/Events
Lumos Pharma management to meet virtually with Oppenheimer » 07:08
09/23/22
09/23
07:08
09/23/22
07:08
LUMO

Lumos Pharma

$9.09 /

+0.49 (+5.70%)

Virtual Meetings to be…

Virtual Meetings to be held September 22-23 hosted by Oppenheimer.

ShowHide Related Items >><<
LUMO Lumos Pharma
$9.09 /

+0.49 (+5.70%)

LUMO Lumos Pharma
$9.09 /

+0.49 (+5.70%)

07/19/22 Oppenheimer
Lumos Pharma initiated with an Outperform at Oppenheimer
05/10/22 Piper Sandler
Upcoming topline data could drive Lumos Pharma share gains, says Piper Sandler
LUMO Lumos Pharma
$9.09 /

+0.49 (+5.70%)

Conference/Events
Lumos Pharma management to meet virtually with Oppenheimer » 14:44
09/22/22
09/22
14:44
09/22/22
14:44
LUMO

Lumos Pharma

$9.09 /

+0.49 (+5.70%)

Virtual Meeting to be…

Virtual Meeting to be held on September 26 hosted by Oppenheimer.

ShowHide Related Items >><<
LUMO Lumos Pharma
$9.09 /

+0.49 (+5.70%)

LUMO Lumos Pharma
$9.09 /

+0.49 (+5.70%)

07/19/22 Oppenheimer
Lumos Pharma initiated with an Outperform at Oppenheimer
05/10/22 Piper Sandler
Upcoming topline data could drive Lumos Pharma share gains, says Piper Sandler
LUMO Lumos Pharma
$9.09 /

+0.49 (+5.70%)

Over a quarter ago
Syndicate
Lumos Pharma files $100M mixed securities shelf  06:28
08/19/22
08/19
06:28
08/19/22
06:28
LUMO

Lumos Pharma

$9.01 /

+0.03 (+0.33%)

 
ShowHide Related Items >><<
LUMO Lumos Pharma
$9.01 /

+0.03 (+0.33%)

LUMO Lumos Pharma
$9.01 /

+0.03 (+0.33%)

07/19/22 Oppenheimer
Lumos Pharma initiated with an Outperform at Oppenheimer
05/10/22 Piper Sandler
Upcoming topline data could drive Lumos Pharma share gains, says Piper Sandler
LUMO Lumos Pharma
$9.01 /

+0.03 (+0.33%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.